<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40802193</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2380-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA cardiology</Title><ISOAbbreviation>JAMA Cardiol</ISOAbbreviation></Journal><ArticleTitle>Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e252611</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamacardio.2025.2611</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Antithrombotic therapy is crucial for older patients with coronary artery disease (CAD) and atrial fibrillation (AF) who are at a high risk of bleeding and thrombotic events.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To examine the age-stratified effects of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet agent combination therapy.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was a post hoc secondary analysis of the Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease (AFIRE) open-label randomized clinical trial. This was a multicenter study conducted in Japan from February 23, 2015, to July 31, 2018. Patients with AF and stable CAD who had undergone percutaneous coronary intervention or coronary artery bypass grafting 1 or more years earlier or who had angiographically confirmed CAD that did not require revascularization were enrolled. Participants were stratified into 4 groups by age (&lt;70 years, 70-74 years, 75-79 years, and &#x2265;80 years). Study data were analyzed from August 2024 to July 2025.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="UNASSIGNED">Rivaroxaban monotherapy or rivaroxaban&#x2009;plus&#x2009;antiplatelet agent therapy.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary efficacy end point was a major adverse cardiovascular event, defined as a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause. The primary safety end point was major bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This study included a total of 2215 participants (mean [SD] age, 74.3&#x2009;[8.2] years; 1751 male [79.1%]). The incidence of primary efficacy end points per patient-year for rivaroxaban monotherapy vs rivaroxaban&#x2009;plus&#x2009;antiplatelet agent therapy was 3.2% vs 4.3% (&lt;70 years), 3.2% vs 2.8% (70-74 years), 3.8% vs 5.3% (75-79 years), and 6.2% vs 10.3% (&#x2265;80 years). The hazard ratios were 0.74 (95% CI, 0.40-1.37) for those younger than 70 years, 1.16 (95% CI, 0.55-2.45) for those aged 70 to 74 years, 0.72 (95% CI, 0.41-1.26) for those aged 75 to 79 years, and 0.61 (95% CI, 0.40-0.93) for those 80 years and older (P for interaction&#x2009;=.51). For the primary safety end points, the incidence was 0.5% vs 2.3% (&lt;70 years), 2.2% vs 2.4% (70-74 years), 1.1% vs 2.1% (75-79 years), and 2.9% vs 4.3% (&#x2265;80 years). The hazard ratios were 0.23 (95% CI, 0.06-0.79) for those younger than 70 years, 0.91 (95% CI, 0.39-2.15) for those aged 70 to 74 years, 0.52 (95% CI, 0.19-1.42) for those aged 75 to 79 years, and 0.67 (95% CI, 0.35-1.27) for those 80 years and older (P for interaction&#x2009;=.33).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Results of this post hoc analysis of the AFIRE randomized clinical trial reveal that rivaroxaban monotherapy reduced the risk of major cardiovascular events and major bleeding across the broad range of age in patients with AF and stable CAD. Possible age-related differences in trends, with more pronounced efficacy in older patients and more pronounced safety in younger patients, should be considered as hypothesis generating and require further research.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT02642419.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Junichi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arashi</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Nobuhisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaikita</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akao</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ako</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kitasato University School of Medicine, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matoba</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyauchi</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Kunihiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine and Primary Care, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Hisao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AFIRE Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02642419</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Cardiol</MedlineTA><NlmUniqueID>101676033</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yamaguchi reported receiving grants from Abbott, Boston Scientific, Terumo, Nippon Boehringer Ingelheim, Bayer Yakuhin, Otsuka Pharmaceutical and personal fees from Abbott, Anges, Daiichi Sankyo, and Kowa outside the submitted work. Dr Hagiwara reported receiving grants from Bayer Yakuhin and Nippon Boehringer Ingelheim during the conduct of the study. Dr Kaikita reported receiving grants from Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and personal fees from Bayer Yakuhin and Daiichi Sankyo outside the submitted work. Dr Akao reported receiving grants from Bayer Yakuhin and personal fees from Bayer Yakuhin, Daiichi Sankyo, and Bristol Myers Squibb outside the submitted work. Dr Ako reported receiving personal fees from Bayer outside the submitted work. Dr Matoba reported receiving grants from Bayer, Kowa, and Novartis outside the submitted work. Dr Nakamura reported receiving grants from Bayer Yakuhin and personal fees from Daiichi Sankyo, Bristol Myers Squibb, and Nippon Boehringer Ingelheim during the conduct of the study and endowments from Boston Scientific Japan, K.K., Asahi Intec Co Ltd Biotronik Japan Inc, Otsuka Medical Device Co Ltd, Kaneka Co, Terumo Corp, Nipro Co, and Japan Life Line Co Ltd. Dr Miyauchi reported receiving personal fees from Bayer during the conduct of the study. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamiya</LastName><ForeName>Eiji</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suetake</LastName><ForeName>Syuji</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Teruo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kojima</LastName><ForeName>Jisho</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suwa</LastName><ForeName>Satoru</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yasu</LastName><ForeName>Takanori</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamada</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arai</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hata</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakanashi</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tateishi</LastName><ForeName>Hironobu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nozaki</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okumura</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tokue</LastName><ForeName>Masahide</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuroki</LastName><ForeName>Norihiro</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishida</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajioka</LastName><ForeName>Masazumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yumoto</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Shogo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aoyama</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimomura</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takeda</LastName><ForeName>Terunori</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oshiro</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugishita</LastName><ForeName>Nobuyoshi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shibata</LastName><ForeName>Yoshisato</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otonari</LastName><ForeName>Takatoshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kihara</LastName><ForeName>Hajime</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ono</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazama</LastName><ForeName>Minoru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsukahara</LastName><ForeName>Kengo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haruta</LastName><ForeName>Seichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haruna</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ito</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atsuchi</LastName><ForeName>Nobuhiko</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sata</LastName><ForeName>Masataka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wakeyama</LastName><ForeName>Takatoshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasebe</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kobayasi</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Osato</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hironaga</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naganuma</LastName><ForeName>Yujiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anzaki</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okazaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tokuhiro</LastName><ForeName>Keichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Momose</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kametani</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawamitsu</LastName><ForeName>Katsunori</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saito</LastName><ForeName>Yoshihiko</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akashi</LastName><ForeName>Shintaro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumagai</LastName><ForeName>Kenta</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eshima</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tobaru</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seo</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okuhara</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozuma</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikari</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oiwa</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michishita</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujikura</LastName><ForeName>Hisanori</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Momomura</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otomo</LastName><ForeName>Kenichiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsubara</LastName><ForeName>Taku</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inoue</LastName><ForeName>Teruo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiojima</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tachibana</LastName><ForeName>Eizo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sumii</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Nobuyasu</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Omura</LastName><ForeName>Nobuhiro</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Naohiko</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morita</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Kouki</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujinaga</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Michiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oka</LastName><ForeName>Takefumi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shirayama</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amano</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukui</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ando</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oshima</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kagiyama</LastName><ForeName>Shuntaro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teragawa</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuge</LastName><ForeName>Masaru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ono</LastName><ForeName>Shiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koga</LastName><ForeName>Tokushi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujiu</LastName><ForeName>Katsuhito</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuwabara</LastName><ForeName>Masanari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oya</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yumoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuji</LastName><ForeName>Naomitsu</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikemura</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kario</LastName><ForeName>Kazuomi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chatani</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyagi</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murakami</LastName><ForeName>Mikitaka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saito</LastName><ForeName>Katumi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoshiga</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>Shinji</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubo</LastName><ForeName>Norifumi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashida</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murasaki</LastName><ForeName>Saroshi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uehara</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akasaka</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oba</LastName><ForeName>Yurika</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Shiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanaoka</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishimiya</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsunoda</LastName><ForeName>Ryusuke</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onuma</LastName><ForeName>Yoshito</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Sadanobu</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tani</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wada</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Masashi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obata</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Yoshiharu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Endo</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Ritsushi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsunaga</LastName><ForeName>Toshiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Tosizo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Usui</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otsuji</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Osaki</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaizen</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshihara</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadota</LastName><ForeName>Kazushige</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirose</LastName><ForeName>Toyoki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyazawa</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takano</LastName><ForeName>Masamitsu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Wataru</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wake</LastName><ForeName>Minoru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oriso</LastName><ForeName>Seizo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshiyama</LastName><ForeName>Minoru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kakinoki</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishioka</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Takefumi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nomoto</LastName><ForeName>Kazumiki</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seki</LastName><ForeName>Kosaburo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miura</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawasaki</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funada</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dote</LastName><ForeName>Keigo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owada</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doke</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubo</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horiuchi</LastName><ForeName>Masataka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagano</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takaishi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Masaya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murozono</LastName><ForeName>Yukichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munemasa</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakata</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inoue</LastName><ForeName>Naoto</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ota</LastName><ForeName>Takehiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamano</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abe</LastName><ForeName>Norihiro</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsubokura</LastName><ForeName>Toshio</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goto</LastName><ForeName>Masami</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubota</LastName><ForeName>Isao</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yano</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Umetani</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Date</LastName><ForeName>Taro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noda</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goto</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hibi</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakano</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiramitsu</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kihara</LastName><ForeName>Yasuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugi</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiba</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Izumi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajiki</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oishi</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiryu</LastName><ForeName>Michiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Tenei</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ando</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Syunichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinugawa</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otake</LastName><ForeName>Hiromasa</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitaoka</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tayama</LastName><ForeName>Shinji</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirata</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honda</LastName><ForeName>Soichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manita</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oka</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nanba</LastName><ForeName>Yasuharu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishino</LastName><ForeName>Masami</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saito</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakai</LastName><ForeName>Hirosumi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Namiuchi</LastName><ForeName>Shigeto</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsui</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inoue</LastName><ForeName>Kanichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komiyama</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akashi</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komaru</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosokawa</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chikamori</LastName><ForeName>Taishiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arasaki</LastName><ForeName>Osamu</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aonuma</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wakasa</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshizawa</LastName><ForeName>Tomoharu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugano</LastName><ForeName>Teruyasu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokota</LastName><ForeName>Naoto</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kakutani</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abe</LastName><ForeName>Yusei</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okayama</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokoi</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chin</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomita</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honzyo</LastName><ForeName>Hirotsugu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Hiroya</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morino</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsujiyama</LastName><ForeName>Shuji</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>Michihiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamasaki</LastName><ForeName>Syuichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niijima</LastName><ForeName>Yawara</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aoyama</LastName><ForeName>Takuma</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maki</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanabe</LastName><ForeName>Kengo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murohara</LastName><ForeName>Toyoaki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naomi</LastName><ForeName>Shojiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Naoya</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minamino</LastName><ForeName>Tohru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sairenji</LastName><ForeName>Hiroshige</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Noriyuki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arikawa</LastName><ForeName>Masaya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ito</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Yoshifusa</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hata</LastName><ForeName>Shiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakatsu</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onodera</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amano</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tokutake</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasao</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moriguchi</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Masazumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Hareaki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yanbe</LastName><ForeName>Yuzuru</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwasawa</LastName><ForeName>Takamasa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Hisao</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shibahashi</LastName><ForeName>Eiji</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takita</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40802193</ArticleId><ArticleId IdType="pmc">PMC12351466</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2025.2611</ArticleId><ArticleId IdType="pii">2837457</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf S, et al. ; RE-LY Steering Committee and Investigators . Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi: 10.1056/NEJMoa0905561</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0905561</ArticleId><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MR, Mahaffey KW, Garg J, et al. ; ROCKET AF Investigators . Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1009638</ArticleId><ArticleId IdType="pubmed">21830957</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, Alexander JH, McMurray JJ, et al. ; ARISTOTLE Committees and Investigators . Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi: 10.1056/NEJMoa1107039</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano RP, Ruff CT, Braunwald E, et al. ; ENGAGE AF-TIMI 48 Investigators . Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi: 10.1056/NEJMoa1310907</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1310907</ArticleId><ArticleId IdType="pubmed">24251359</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura K, Akao M, Yoshida T, et al. ; ELDERCARE-AF Committees and Investigators . Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020;383(18):1735-1745. doi: 10.1056/NEJMoa2012883</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2012883</ArticleId><ArticleId IdType="pubmed">32865374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotalczyk A, Guo Y, Fawzy AM, Wang Y, Lip GYH. Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. J Arrhythm. 2022;38(4):580-588. doi: 10.1002/joa3.12744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/joa3.12744</ArticleId><ArticleId IdType="pmc">PMC9347193</ArticleId><ArticleId IdType="pubmed">35936042</ArticleId></ArticleIdList></Reference><Reference><Citation>Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv. 2014;7(1):113-124. doi: 10.1161/CIRCINTERVENTIONS.113.001150</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.113.001150</ArticleId><ArticleId IdType="pubmed">24550531</ArticleId></ArticleIdList></Reference><Reference><Citation>Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease&#x2014;double trouble. Adv Med Sci. 2018;63(1):30-35. doi: 10.1016/j.advms.2017.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2017.06.005</ArticleId><ArticleId IdType="pubmed">28818746</ArticleId></ArticleIdList></Reference><Reference><Citation>Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(1):83-99. doi: 10.1016/j.jacc.2019.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.05.016</ArticleId><ArticleId IdType="pubmed">31272556</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 Update. Circulation. 2021;143(6):583-596. doi: 10.1161/CIRCULATIONAHA.120.050438</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050438</ArticleId><ArticleId IdType="pubmed">33555916</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;n&#xe9;reux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of postdischarge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036-1045. doi: 10.1016/j.jacc.2015.06.1323</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.06.1323</ArticleId><ArticleId IdType="pubmed">26314532</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf. 2019;18(12):1171-1189. doi: 10.1080/14740338.2019.1680637</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2019.1680637</ArticleId><ArticleId IdType="pubmed">31623473</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.040167</ArticleId><ArticleId IdType="pmc">PMC6636810</ArticleId><ArticleId IdType="pubmed">31116032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda S, Kaikita K, Akao M, et al. ; AFIRE Investigators . Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103-1113. doi: 10.1056/NEJMoa1904143</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1904143</ArticleId><ArticleId IdType="pubmed">31475793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda S, Kaikita K, Ogawa H, et al. Atrial fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease (AFIRE): protocol for a multicenter, prospective, randomized, open-label, parallel group study. Int J Cardiol. 2018;265:108-112. doi: 10.1016/j.ijcard.2018.04.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2018.04.131</ArticleId><ArticleId IdType="pubmed">29764706</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3(4):692-694. doi: 10.1111/j.1538-7836.2005.01204.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01204.x</ArticleId><ArticleId IdType="pubmed">15842354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashedi S, Keykhaei M, Sato A, et al. Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials. J Am Coll Cardiol. 2025;85(11):1189-1203. doi: 10.1016/j.jacc.2024.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.12.030</ArticleId><ArticleId IdType="pubmed">39918465</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4)(suppl S):62S-69S. doi: 10.1016/S0735-1097(02)02776-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)02776-6</ArticleId><ArticleId IdType="pubmed">12644343</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Baim DS, Popma JJ, et al. ; Stent Anticoagulation Restenosis Study Investigators . A clinical trial comparing 3 antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339(23):1665-1671. doi: 10.1056/NEJM199812033392303</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199812033392303</ArticleId><ArticleId IdType="pubmed">9834303</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly S, Pogue J, Hart R, et al. ; ACTIVE Writing Group of the ACTIVE Investigators . Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367(9526):1903-1912. doi: 10.1016/S0140-6736(06)68845-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)68845-4</ArticleId><ArticleId IdType="pubmed">16765759</ArticleId></ArticleIdList></Reference><Reference><Citation>Matoba T, Yasuda S, Kaikita K, et al. ; AFIRE Investigators . Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights From the AFIRE Trial. JACC Cardiovasc Interv. 2021;14(21):2330-2340. doi: 10.1016/j.jcin.2021.07.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2021.07.045</ArticleId><ArticleId IdType="pubmed">34736731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. doi: 10.1056/NEJMoa1611594</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1611594</ArticleId><ArticleId IdType="pubmed">27959713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon CP, Bhatt DL, Oldgren J, et al. ; RE-DUAL PCI Steering Committee and Investigators . Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-1524. doi: 10.1056/NEJMoa1708454</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1708454</ArticleId><ArticleId IdType="pubmed">28844193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, Heizer G, Aronson R, et al. ; AUGUSTUS Investigators . Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi: 10.1056/NEJMoa1817083</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1817083</ArticleId><ArticleId IdType="pubmed">30883055</ArticleId></ArticleIdList></Reference><Reference><Citation>Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-Based vs Vitamin K Antagonist-Based Antithrombotic Regimen After Successful Coronary Stenting in Patients With Atrial Fibrillation (ENTRUST-AF PCI): a randomized, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31872-0</ArticleId><ArticleId IdType="pubmed">31492505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129(15):1577-1585. doi: 10.1161/CIRCULATIONAHA.113.004834</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.004834</ArticleId><ArticleId IdType="pubmed">24470482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, Kimura K, Kimura T, et al. JCS 2020 guideline-focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84(5):831-865. doi: 10.1253/circj.CJ-19-1109</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-19-1109</ArticleId><ArticleId IdType="pubmed">32173684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks G, Potpara T, Dagres N, et al. ; ESC Scientific Document Group . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa612</ArticleId><ArticleId IdType="pubmed">32860505</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglar JA, Chung MK, Armbruster AL, et al. ; Peer Review Committee Members . 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaikita K, Yasuda S, Akao M, et al. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE Trial. Circ Cardiovasc Interv. 2021;14(11):e010476. doi: 10.1161/CIRCINTERVENTIONS.120.010476</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.120.010476</ArticleId><ArticleId IdType="pubmed">34474583</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MS, Kang DY, Ahn JM, et al. ; EPIC-CAD Investigators . Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391(22):2075-2086. doi: 10.1056/NEJMoa2407362</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2407362</ArticleId><ArticleId IdType="pubmed">39225258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with nonvalvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59-70. doi: 10.2133/dmpk.DMPK-12-RG-034</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.DMPK-12-RG-034</ArticleId><ArticleId IdType="pubmed">22813718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>